Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Key Companies Innovating in GLP-1 Obesity Treatments In 2025, the landscape of obesity treatment is being reshaped by innovative companies developing GLP-1 (glucagon-like peptide-1) receptor agonists
As a result, retatrutide has emerged as a valuable research tool for studying obesity, type 2 diabetes mellitus, insulin resistance, metabolic dysfunction-associated steatotic liver disease (MASLD/NASH), cardiovascular-metabolic disorders, and energy homeostasis
Nat Reviews Disease Primers
The weight loss numbers below come from three separate clinical trials, each with different patients and different durations
US$ 24.56
US$ 26.53
US$ 20.14
US$ 24.40
US$ 29.29
US$ 27.79
US$ 28.66
US$ 27.06
